{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/003/SRR5638583/SRR5638583_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/000/SRR5638580/SRR5638580_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/005/SRR5638585/SRR5638585_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/001/SRR5638581/SRR5638581_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/002/SRR5638582/SRR5638582_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/006/SRR5638586/SRR5638586_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/003/SRR5638583/SRR5638583_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/002/SRR5638582/SRR5638582_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/001/SRR5638581/SRR5638581_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/009/SRR5638589/SRR5638589_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/004/SRR5638584/SRR5638584_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/007/SRR5638587/SRR5638587_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/009/SRR5638579/SRR5638579_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/008/SRR5638588/SRR5638588_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/006/SRR5638586/SRR5638586_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/009/SRR5638589/SRR5638589_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/008/SRR5638578/SRR5638578_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/007/SRR5638587/SRR5638587_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/004/SRR5638584/SRR5638584_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/008/SRR5638578/SRR5638578_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/005/SRR5638585/SRR5638585_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/000/SRR5638580/SRR5638580_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/008/SRR5638588/SRR5638588_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR563/009/SRR5638579/SRR5638579_1.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Center of Applied Genomics, Children's Hospital of Philadelphia"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA388966"],"scientific_name":["Homo sapiens"],"long_description":["Telomerase promoter mutations are highly prevalent in human tumors including melanoma. Telomere transcriptional signatures are enriched in a subset of therapy-naïve melanomas associated with worse overall survival, in BRAF-mutant intrinsically resistant melanoma cells that evade MAPK inhibitors (MAPKi), as well as in a subset of post-treatment tumor biopsies derived from patients who have disease progression on MAPKi or the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD1. We demonstrate the efficacy of a telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG) that results in telomere dysfunction and cell death in various models of therapy-resistant cells. Furthermore, 6-thio-dG significantly inhibits tumor growth of primary tumor biopsy cultures derived from patients who had disease progression on multiple therapies including anti-CTLA-4 or anti-PD1. Overall design: A375 and LOX-IMVI BR melanoma cells were treated with the control, 6-Thio-dG and BIBR 1532. RNA was purified from two biological replicates for RNA sequencing."],"tag":["xref:PubMed:29563139"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Homo sapiens","description":"Gene Expression Analysis of Melanoma Cells Treated with 6-Thio-dG In Vitro","dates":{"last_updated":"2025-09-24","first_public":"2017-06-04"},"accession":"PRJNA388966","cross_references":{"GEO":["GSE99552"],"taxon":["9606"],"PubMed":["29563139"]}}